Ardelyx Inc Quick Ratio (ARDX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Ardelyx inc   (NASDAQ: ARDX)

Ardelyx Inc 's Quick Ratio

ARDX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 2.13 below Ardelyx Inc average.

Within Major Pharmaceutical Preparations industry 284 other companies have achieved higher Quick Ratio than Ardelyx Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1354 to 1367.

Explain Quick Ratio?
How much Cash & cash equivalents ARDX´s has?
What are ARDX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ARDX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 61.79 % 44.47 % 13.84 % 18.28 % 30.89 %
Y / Y Cash & cash equivalent Change 18.19 % 11.27 % 5.83 % 27.47 % 28.23 %
Quick Ratio MRQ 2.13 2.17 2.99 2.91 2.92
ARDX's Total Ranking # 1367 # 1354 # 1252 # 1282 # 1340
Seq. Current Liabilities Change 20.67 % 23.66 % 6.26 % 2.04 % 7.76 %
Seq. Cash & cash equivalent Change 18.38 % -10.06 % 9.06 % 1.78 % 11.45 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 285
Healthcare Sector # 489
Overall Market # 1357


Quick Ratio Statistics
High Average Low
25.52 6.2 1.66
(Jun 30 2015)   (Jun 30 2022)




Financial Statements
Ardelyx Inc 's Current Liabilities $ 132 Millions Visit ARDX's Balance sheet
Ardelyx Inc 's Cash & cash equivalent $ 282 Millions Visit ARDX's Balance sheet
Source of ARDX's Sales Visit ARDX's Sales by Geography


Cumulative Ardelyx Inc 's Quick Ratio

ARDX's Quick Ratio for the trailling 12 Months

ARDX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 35.27 % 26.75 % 23.12 % 32.7 % 43.44 %
Y / Y Cash & cash equivalent TTM Growth 15.05 % 17.08 % 15.77 % 23.84 % 21 %
Quick Ratio TTM 2.48 2.71 2.91 2.97 2.92
Total Ranking TTM # 1726 # 1922 # 1406 # 1375 # 1544
Seq. Current Liabilities TTM Growth 13.9 % 10.23 % 3.38 % 4.21 % 6.73 %
Seq. Cash & cash equivalent TTM Growth 4.41 % 2.51 % 1.54 % 5.86 % 6.25 %

Quick ratio ranking by company, industry and sector >> Back to ARDX Financial Strength Comparisons >> Go to Compare ARDX Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q2 2026 to $132.22 millions, cumulative Quick Ratio decreased to 2.48 below the Ardelyx Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 437 other companies have achieved higher Quick Ratio than Ardelyx Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3706.

Explain Quick Ratio?
How much Cash & cash equivalents ARDX´s has?
What are ARDX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 438
Healthcare Sector # 901
Within the Market # 1367


trailing twelve months Quick Ratio Statistics
High Average Low
14.34 3.89 0.57
(Mar 31 2016)   (Mar 31 2024)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Zymeworks Inc   5.73 $ 270.699  Millions$ 47.243  Millions
Tonix Pharmaceuticals Holding Corp   5.72 $ 176.232  Millions$ 30.785  Millions
Emmis Acquisition Corp   5.72 $ 0.708  Millions$ 0.124  Millions
Arcturus Therapeutics Holdings Inc   5.71 $ 191.483  Millions$ 33.536  Millions
Hoth Therapeutics Inc   5.70 $ 7.892  Millions$ 1.384  Millions
Silence Therapeutics Plc  5.67 $ 72.100  Millions$ 12.714  Millions
Adial Pharmaceuticals Inc   5.51 $ 28.200  Millions$ 5.121  Millions
Corbus Pharmaceuticals Holdings Inc   5.49 $ 117.941  Millions$ 21.483  Millions
Bio Green Med Solution Inc   5.48 $ 3.790  Millions$ 0.692  Millions
Arrowhead Pharmaceuticals Inc   5.47 $ 1,551.301  Millions$ 283.346  Millions
Context Therapeutics Inc   5.45 $ 42.990  Millions$ 7.885  Millions
Annexon Inc   5.44 $ 209.200  Millions$ 38.482  Millions
Mereo Biopharma Group Plc  5.37 $ 30.506  Millions$ 5.677  Millions
Cns Pharmaceuticals Inc   5.35 $ 19.985  Millions$ 3.738  Millions
Neurogene Inc   5.23 $ 112.485  Millions$ 21.505  Millions
Lexaria Bioscience Corp   5.20 $ 3.642  Millions$ 0.701  Millions
Barinthus Biotherapeutics Plc  5.19 $ 59.295  Millions$ 11.423  Millions
Immuneering Corporation  5.14 $ 41.731  Millions$ 8.116  Millions
Lyell Immunopharma Inc   5.12 $ 204.102  Millions$ 39.867  Millions
Altimmune inc   5.04 $ 63.008  Millions$ 12.501  Millions
Rani Therapeutics Holdings Inc   5.02 $ 53.391  Millions$ 10.638  Millions
Phio Pharmaceuticals Corp  4.99 $ 12.996  Millions$ 2.606  Millions
Immunic Inc   4.96 $ 155.098  Millions$ 31.260  Millions
Silo Pharma Inc  4.90 $ 5.227  Millions$ 1.066  Millions
Atossa Therapeutics Inc   4.81 $ 26.204  Millions$ 5.451  Millions
Calcimedica Inc   4.71 $ 18.600  Millions$ 3.950  Millions
Kala Bio inc   4.70 $ 7.229  Millions$ 1.538  Millions
Septerna Inc   4.69 $ 372.322  Millions$ 79.316  Millions
Viking Therapeutics Inc   4.57 $ 501.663  Millions$ 109.656  Millions
Camp4 Therapeutics Corporation  4.51 $ 86.398  Millions$ 19.142  Millions

Date modified: 2026-09-26T07:08:33+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.